# Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

> **NCT03862885** · — · APPROVED_FOR_MARKETING · sponsor: **Blueprint Medicines Corporation**

## Conditions studied

- GIST

## Interventions

- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT03862885
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862885, "Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03862885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*